<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01152346</url>
  </required_header>
  <id_info>
    <org_study_id>AZFAST101</org_study_id>
    <nct_id>NCT01152346</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients</brief_title>
  <official_title>A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioniche Pharma USA LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioniche Pharma USA LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the bioavailability of Azacitidine for Injection
      relative to Vidaza® in MDS patients under fasting conditions. The data will be evaluated
      statistically to determine if the products meet bioequivalence criteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open label, multi-center randomized, single dose, two-treatment, two-period,
      two-sequence, two-way cross-over, relative bioavailability study of Azacitidine for Injection
      for suspension use manufactured for Bioniche Pharma USA LLC compared with Vidaza®
      manufactured by Celgene Corporation in MDS patients under fasting conditions. Patients who
      are on a stable 75 mg/m2 dose of Vidaza will be randomized to study drug sequence Azacitidine
      on C1D1/ Vidaza® on C2D1 or Vidaza® on C1D1 / Azacitidine on C2D1. Randomization will be in a
      2:2 ratio. Thirty-six (36) patients will be enrolled to ensure 28 evaluable patients.
      Patients will not be blinded to their treatment assignment.

      After randomization, fasted patients will receive 1 dose of assigned study drug (either
      Azacitidine for Injection or Vidaza®) subcutaneously at a dose of 75 mg/m2 on C1D1. On Days
      2-7, they will receive their normal Vidaza® treatment. Following a 21 day rest period,
      patients will cross over to receive the alternate treatment on C2D1 followed by their normal
      Vidaza®) treatment on Cycle 2 Days 2-7. The Final Patient Visit will be conducted 7 days
      following the last dose of Vidaza®.

      The total duration of the study for each patient will be up to 56 days including the
      Screening period and Post Study Visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Azacitidine in Plasma Samples for Determination of Cmax, AUC0-t, and AUC0-Inf</measure>
    <time_frame>13 timepoints from pre-dose to 8 hours post dose</time_frame>
    <description>Pharmacokinetic samples will be collected pre-dose and at 12 timepoints post-dose for determination of the level of azacitidine. The relative bioavailability of test to reference drug will be evaluated. If the Cmax, AUC0-t and AUC0-inf 90% confidence intervals for the geometric mean ratio all lie within 80-125% for Azacitidine then bioequivalence is concluded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Throughout study</time_frame>
    <description>Safety will be assessed through monitoring of adverse events and laboratory measures.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence- Azacitidine followed by Vidaza®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sequence-Vidaza® followed by Azacitidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine for Injection</intervention_name>
    <description>75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment</description>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_label>ARM 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vidaza®</intervention_name>
    <description>75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment</description>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_label>ARM 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with age &gt;18 years.

          -  Patients with Myelodysplastic Syndrome (MDS) placed on Vidaza® according to the
             Marketing Authorization issued in the country in which the clinical study is being
             conducted (i.e., in the US, patients with any of the following French-American-British
             ( FAB) subtypes: Refractory Anemia (RA), Refractory Anemia with Ringed Sideroblasts
             (RARS), (if accompanied by neutropenia or thrombocytopenia or requiring transfusions),
             Refractory Anemia with Excess Blasts (RAEB), Refractory Anemia with Excess Blasts in
             Transformation (RAEB-T) and Chronic Myelomonocytic Leukemia (CMMoL); in France,
             subjects who are not eligible for hematopoietic stem cell transplantation: with
             intermediate -2 and high-risk myelodysplastic syndromes according to the International
             Prognostic Scoring System (IPSS) or chronic myelomonocytic leukemia (CMML) with 10-29%
             marrow blasts without myeloproliferative disorder) and who currently receive Vidaza at
             75 mg/m2;

          -  Patient life expectancy &gt; 6 months.

          -  Patients with performance status of 0 - 2 as per ECOG Scale.

          -  Patients with Total Bilirubin &lt; 1.5 x ULN; ALT/AST &lt; 2 x ULN, Serum Creatinine &lt; 1.5
             ULN, Serum Bicarbonate &gt; 19 mEq/L.

          -  Patients who have signed the Informed Consent Form.

        Exclusion Criteria:

          -  Patients with a history of alcoholism or drug addiction (during past 2 years)

          -  Patients with severe hepatic impairment, impaired renal function, and any condition
             which in the Investigator's opinion would be contraindicated or would interfere with
             absorption of the study drug.

          -  Patients whose clinical laboratory test values are outside the reference range may be
             re-tested at the discretion of the Investigator. If the clinical values are outside
             the range on re-testing, the patient will not be eligible to participate in the study
             unless the Investigator deems the result not to be significant.

          -  Patients with any other active malignancy within the past 5 years except for cervical
             cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the
             skin.

          -  Patients who have a history of allergic responses to the class of drug being tested.

          -  Patients with hypersensitivity to Mannitol.

          -  Patients should not have donated blood and/or plasma for at least thirty (30) days
             prior to the first dosing of the study drug. Patients should not have had any
             transfusion of blood products for at least 7 days prior.

          -  Patients who have taken any investigational drug within thirty (30) days prior to the
             first dosing of the study.

          -  Female patients who are pregnant, breast-feeding, or who are likely to become pregnant
             during the study. Female patients of child bearing potential will be instructed to
             either abstain from sexual intercourse or use an acceptable method of birth control
             during the course of the study and for 3 months afterward. Male patients or their
             female partners should also use an acceptable method of birth control.

          -  Any patient whom the Investigator believes will not be a good candidate for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre FENAUX, MD Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Service d'hématologie clinique- Hôpital Avicenne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel GYAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre régional de cancérologie Henry-Kaplan Service d'Hématologie et thérapie cellulaire-Hôpital Bretonneau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Agnès-Paule GUERCI-BRESLER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'hématologie et de médecine interne-Hôpital de Brabois</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Richard Eveillard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Brest- Hôpital Morvan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Odile BEYNE-RAUZY, MD Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurence LEGROS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Archet 1</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mauricette MICHALLET, MD Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Edouard Herriot</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krimo Bouabdallah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Haut-Lévêque</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal Cony-Makhoul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Annecy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manjesh Lingamurthy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Holy Cross Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Hager, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Cancer Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Misagh Karimi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wilshire Oncology Medical Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Veena Charu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pacific Cancer Medical Center Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center Inc.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilshire Oncology Medical Group</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'hématologie clinique Hôpital Avicenne</name>
      <address>
        <city>Bobigny cedex</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest- Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Archet 1</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Annecy</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre régional de cancérologie Henry-Kaplan Service d'Hématologie et thérapie cellulaire</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'hématologie et de médecine interne CHU de Nancy Hôpital de Brabois</name>
      <address>
        <city>Vandoeuvre</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2010</study_first_submitted>
  <study_first_submitted_qc>June 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2010</study_first_posted>
  <last_update_submitted>January 27, 2015</last_update_submitted>
  <last_update_submitted_qc>January 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Azacitidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

